Clinical Trials Directory

Trials / Completed

CompletedNCT00786708

Sensitivity and Specificity of NGAL in an Emergency Room Population

Sensitivity and Specificity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in an Emergency Room Population

Status
Completed
Phase
Study type
Observational
Enrollment
2,304 (actual)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypothesis: In patients that present to an urban emergency room, a single urine neutrophil gelatinase-associated lipocalin (NGAL) measurement can classify their kidney disease as stable chronic kidney disease, acute tubular necrosis, urinary outlet obstruction or pre-renal azotemia.

Detailed description

The purpose of this study is to determine whether urinary NGAL levels are able to distinguish the classical categories of renal disease. Previous studies have strongly suggested that this protein marks those with fulminant renal dysfunction with greater sensitivity and time resolution than currently used markers. Studies to date have been in highly selected populations: children and adults following cardiac surgery, infants with cardiovascular anomalies, and patients with known chronic kidney disease. Demonstration of similarly robust sensitivity and specificity in a broad Emergency Room population would strengthen the conception of NGAL as a marker of early or advancing kidney dysfunction. Most importantly, if NGAL can distinguish between types of renal disease at presentation in the ER, it might have important implications regarding ER management of these common presentations. For example, it could reduce diagnostic ambiguity and lag time from hours or days to seconds.

Conditions

Timeline

Start date
2006-12-01
Primary completion
2009-12-01
Completion
2013-07-01
First posted
2008-11-06
Last updated
2014-02-10

Locations

3 sites across 2 countries: United States, Germany

Source: ClinicalTrials.gov record NCT00786708. Inclusion in this directory is not an endorsement.